Clinical trials: HAART-treated
HIV Infections
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
- Trial name
- NCT00528957
- Testing
- Tenofovir DF, Zidovudine, Stavudine
- Where
- 9 sites in United States, Panama and 1 more
- Volunteers
- 97 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human…
- Trial name
- NCT00352053
- Testing
- Tenofovir DF
- Where
- 18 sites in Brazil, Panama
- Volunteers
- 87 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
- Trial name
- INTENSE (NCT00487188)
- Testing
- Enfuvirtide, Highly active antiretroviral treatment (HAART)
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing highly active antiretroviral therapy (HAART)…
- Trial name
- TOTEM (NCT00323492)
- Testing
- Truvada, Current HAART regimen
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
HIV Infection
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered topically with DermaPrep to target Langerhans cells.
- Trial name
- GIHU004 (NCT00712530)
- Testing
- DermaVir, HAART
- Where
- Hungary
- Volunteers
- 9 people
- Sponsor
- Genetic Immunity
HIV Infections
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV…
- Trial name
- NCT00445146
- Testing
- EVG, RTV, ARV regimen
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
HIV Infection
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.
- Trial name
- NCT00326716
- Testing
- Atazanavir + Ritonavir + Combivir
- Where
- 6 sites in United States, Puerto Rico and 1 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb